Branded vs compounded GLP-1s in 2026
Jillian Foglesong Stabile, MD
Board-certified Family Medicine · Diplomate, ABOM · Reviewed Jun 5, 2026
You have seen the price difference. A branded GLP-1 pen can run over a thousand dollars a month. A compounded preparation is advertised for a fraction of that. Before you decide, it helps to understand what you are actually comparing. These are not two prices for the same thing. They are two different categories of medication, made under different rules, with different oversight. Here is what those differences mean in plain language.
The short answer
A branded GLP-1 is a finished, FDA-approved medicine dispensed exactly as the manufacturer made it. A compounded GLP-1 is a distinct preparation made by a state-licensed 503A pharmacy for one specific patient, under a patient-specific prescription. It is not the branded product, not a generic, and not FDA-approved. The price gap is real. So is the difference.
What you will learn
- What “branded” and “compounded” actually mean in plain language
- Why a compounded GLP-1 is not a generic and not the same as the brand
- What the FDA changed in 2026 and what it does not touch
- Why several telehealth companies moved toward branded products this year
- The questions a careful patient asks before choosing either path
Chapter 01 · The basics
Two different things, not two prices for one thing
Branded means the medicine you have read about in the headlines. Wegovy® and Ozempic® are brand names for semaglutide. Zepbound® and Mounjaro® are brand names for tirzepatide. The manufacturer runs the clinical trials, the FDA reviews the data, and the finished pen or vial is produced to one approved specification. When you fill a branded prescription, you get that exact approved product.
That approval matters. It means the specific product was studied for safety and effectiveness and is made under federal manufacturing oversight. It is also why branded products carry the prices you have seen.
Compounding is when a licensed pharmacy prepares a medication for an individual patient, rather than dispensing a mass-produced finished drug. In the GLP-1 world, compounding is done by what is called a 503A pharmacy, named for the section of federal law that governs it.
A 503A pharmacy can prepare a medication only against a patient-specific prescription, written for one named person, when a prescriber has determined that the commercially available product does not meet that patient's clinical need. It is a distinct preparation made for that patient. It is not the branded product, and it is not a generic copy of it.
Chapter 02 · The key distinction
Not a generic, and not the same as the brand
This is the single most important point in this article, so read it carefully. A compounded GLP-1 is not a generic version of Wegovy®, Ozempic®, Zepbound®, or Mounjaro®. A true generic is an FDA-approved copy of a brand, shown through its own approval process to perform like the brand. No generic exists yet for any of these medicines.
A compounded preparation is a separate, pharmacy-made product for one patient. It has not gone through FDA approval and is not represented as matching or replacing the branded product.
People reach for the word “generic” the way they would with everyday over-the-counter medicines. The comparison does not hold for compounded GLP-1s. A generic medicine goes through its own FDA approval to demonstrate it performs like the brand. A compounded medication does not go through that process. It is prepared by a pharmacy for a single patient, and it is not represented as matching or replacing the branded product. When a website calls a compounded GLP-1 a “generic,” that is a claim the product cannot support.
Think of it this way: the brand is one defined, approved product. A compounded preparation is something a licensed pharmacy makes for you, the individual, under your prescription. Different category, different rules, different conversation with your clinician.
What would you actually pay?
30-second cost calculator
Chapter 03 · The 2026 rules
What the FDA changed, and what it left alone
In 2026 the FDA tightened the rules on large-scale GLP-1 compounding, but it did not end patient-specific compounding. On April 30, 2026, the FDA proposed leaving semaglutide, tirzepatide, and liraglutide off the 503B “bulks” list, finding no clinical need to mass-compound them now that shortages have resolved. That proposal targets large-batch facilities, not the patient-specific path.
There are two kinds of compounding, and the difference is the whole story here. A 503B “outsourcing facility” makes larger batches, often without a prescription for a named patient in hand. A 503A pharmacy makes a preparation for one specific patient against that patient's prescription.
The FDA's April 30, 2026 proposal concerns the 503B bulk path. The agency found no clinical need to keep mass-compounding these drugs from bulk substances now that the shortages are over. Tirzepatide came off the shortage list in 2024, and semaglutide came off in 2025. Public comment on the proposal runs through June 29, 2026.
The proposal addresses bulk 503B compounding. Patient-specific 503A compounding remains permitted when a prescriber documents that the commercially available product does not meet a specific patient's clinical need. The legal test is patient need, written into the prescription, not a shortage.
The headline “FDA cracks down on compounded GLP-1s” is partly true and partly misleading. The bulk supply that fed a lot of cheap online offers is being squeezed. The narrow, patient-specific path, used when a clinician documents a real clinical reason for it, stays open.
Chapter 04 · Side by side
How the two paths compare
People rarely care about the legal sections. They care about cost, safety oversight, and whether the medicine is right for them. Here is how branded and compounded GLP-1s line up across those questions, with the honest caveats attached.
| Branded GLP-1 | Compounded GLP-1 (503A) | |
|---|---|---|
| What it is | FDA-approved finished product from the manufacturer | A distinct preparation made by a state-licensed pharmacy for one patient |
| Examples | Semaglutide (Wegovy®, Ozempic®); tirzepatide (Zepbound®, Mounjaro®) | Compounded semaglutide or tirzepatide, prepared per prescription |
| Is it a generic? | It is the brand | No. Not a generic and not represented as matching the brand |
| Who authorizes it | Prescribed, then dispensed as made | Prescribed for a named patient with documented clinical need |
| Regulatory oversight | FDA approval and manufacturing oversight | State board of pharmacy; federal 503A compounding rules |
| Typical cost | Higher; see current branded pricing | Often lower; varies by pharmacy and prescription |
| Efficacy data | From the brand's own clinical trials | No separate trial; brand trial data describes the brand, not a compounded prep |
This table is educational, not a recommendation. Whether either path is appropriate is decided by a licensed clinician. Swipe to see the full table on a phone.
On effectiveness, one caution matters. The well-known trial averages belong to the branded products. In head-to-head data published in 2025, branded tirzepatide produced a higher average body-weight reduction than branded semaglutide over 72 weeks. Those figures describe the studied branded products, and individual results vary. They are not a promise, and they are not a measurement of any compounded preparation.
SURMOUNT-5
trial: tirzepatide vs semaglutide head-to-head, 72 weeks, 2025
503A
the patient-specific compounding path still permitted in 2026
Trial figures are group averages for the studied branded products. Individual results vary. No figure applies to any compounded preparation.
Chapter 05 · The market
Why telehealth companies moved toward branded products
The market itself shifted in 2026, which is part of why this question feels confusing right now. As the rules tightened, several large telehealth companies pulled back from advertising compounded GLP-1s and leaned into branded products instead.
The clearest example: in March 2026, a major telehealth company settled with a manufacturer, stopped advertising compounded semaglutide, and moved to branded options, keeping compounded only where a documented clinical reason exists. Other companies repositioned in the same direction. The whole category is recalibrating around the new regulatory line.
What this means for you as a patient: the standard you hold a provider to is now the real differentiator. The medicine matters, but how a provider handles the branded-versus-compounded decision matters just as much. A careful provider does not push one path because it is cheaper to supply. It chooses the path that fits your clinical situation and tells you plainly which one you are getting and why.
A good GLP-1 provider tells you, in writing, whether you are receiving a branded product or a patient-specific compounded preparation, and why that choice was made for you specifically.
A good GLP-1 provider also explains the full monthly cost, the recurring charge, and how to cancel at any time without a phone call before you commit. If a provider cannot give you all of that in writing, that tells you something. This is the standard sipra was built around.
This article is educational and is not medical advice. It does not diagnose, recommend, or prescribe. Treatment decisions, including whether a branded or compounded medication is appropriate, are made with a licensed clinician. Individual results vary.
Your next three steps
You do not have to untangle the 2026 rules on your own. The right answer is the one a clinician reaches with you, for your situation, on your terms.
- Know the difference. Branded is FDA-approved. Compounded is a distinct, patient-specific preparation. Not the same category.
- Ask the right questions. Before you commit: which path am I on, why was it chosen for me, and what is the full recurring cost?
- Talk to a clinician. A blog cannot choose your treatment. A licensed physician reviews your history and decides with you.
Make the informed choice.
Lose weight with a plan made just for you
- Same-day doctor visits and prescriptions
- Semaglutide, tirzepatide & other GLP-1s
- FSA & HSA eligible with all plans
From$79/mo
+ Sipra membership*
*Price includes medication only. Active $99/mo Sipra membership required.
Frequently asked questions
Sources
- U.S. Food and Drug Administration. "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List." Press announcement, dated April 30, 2026. fda.gov
- Foley & Lardner LLP. "FDA Clarifies Policies for Pharmacy Compounders of GLP-1 Products." Dated April 2026. foley.com
- Frier Levitt. "GLP-1 Agonist Compounding by 503A and 503Bs When Removed from the FDA Shortage List." Dated 2026. frierlevitt.com
- Orrick. "FDA Moves to Shut the Door on Large-Scale Compounding of GLP-1 Drugs." Dated May 2026. orrick.com
- Pharmacy Times. "FDA Moves to Permanently Close the Door on Compounded GLP-1s." Dated May 2026. pharmacytimes.com
- Eli Lilly and Company. "Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine." Dated May 2025. investor.lilly.com
- STAT News. "Hims & Hers settles with Novo Nordisk, ends advertised compounded semaglutide." Dated March 2026. statnews.com
- _Last reviewed June 5, 2026 by, sipra Medical Review. This article is educational and is not medical advice. It does not diagnose, recommend, or prescribe. Treatment decisions, including whether a branded or compounded medication is appropriate, are made with a licensed clinician. Individual results vary._
Trademark attribution. Ozempic®, Rybelsus®, and Wegovy® are registered trademarks of Novo Nordisk A/S. Zepbound® and Mounjaro® are trademarks of Eli Lilly and Company. sipra is not affiliated with or endorsed by these companies.
Medically reviewed by
Jillian Foglesong Stabile, MD, FAAFP, DABOM
Was this helpful?
Keep reading
Weight LossGLP-1 weight loss 101: how semaglutide and tirzepatide actually work
17 min read
Weight LossHow GLP-1 Treatment With sipra Works, Step by Step
16 min read
Weight LossThe Real Cost of GLP-1 Medication: Every Number Before Your Card Is Charged
16 min read
Weight LossGLP-1 Myths That Won't Die (and the Facts That Beat Them)
9 min read
Weight LossGLP-1 Side Effects and How to Manage Them, Week by Week
10 min read
Weight LossHow GLP-1s work in the body: the science of appetite and satiety
9 min read
Weight LossWhat 503A compounding means (and why your prescription is made for you)
11 min read
Weight LossWho Should Not Take a GLP-1? Contraindications a Physician Screens For
9 min read